Compare Moderna, Inc. (MRNA) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Tenet Healthcare Corporation — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Tenet Healthcare Corporation trades at $196.03 (market cap $16.74B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, Tenet Healthcare Corporation nearer its low. Which is the better fit depends on your goals.
| MRNA | THC | |
|---|---|---|
Market Cap | $23.60B | $16.74B |
Sector | Health | Health |
52-Week High | $81.80 | $244.80 |
52-Week Low | $22.36 | $148.38 |
Enterprise Value | $19.70B | $26.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Tenet Healthcare (THC) trades at $194.38, down 0.27% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten EPS estimates for three consecutive quarters, with a Q2 2026 report due July 24. Valuation metrics appear attractive with a P/E of 10.11 and P/S of 0.79. Revenue and net income are projected to grow in 2026, supported by expansion in outpatient care.
The outlook is positive given analyst consensus with 81% buy ratings and a $234.63 price target, implying 21% upside. Risks include potential pressure from lower patient days and high debt levels. Earnings growth and ambulatory care performance remain key catalysts for near-term momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
